Figure S6.

The potential anti-angiogenic effects of IGFR inhibition and other MTAs. Hep3B cells were injected subcutaneously into male BALB/c athymic nude mice. Mice were treated daily by gavage as indicated (NVP-30, NVP-AEW541 30 mg/kg/day; Sor-10, sorafenib 10 mg/kg/day; Sun-40, sunitinib 40 mg/kg/day). Tumor microvessel density (MVD) was measured by CD31 immunohistochemical staining (animal number n = 4 in each group). \*\*, P < 0.01, compared with the control (vehicle-treated) group.

